https://doi.org/10.55788/2c350e22
Results of the phase 3 CheckMate 901 trial (NCT03036098) demonstrated that nivolumab plus gemcitabine/cisplatin was beneficial over gemcitabine/cisplatin alone in patients with previously untreated unresectable or mUC [1]. Lymph-node-only metastatic disease is a favourable prognostic factor in mUC. Therefore, a post-hoc analysis of CheckMate 901 was conducted to characterise outcomes in this subpopulation. Prof. Matthew Galsky (Tisch Cancer Institute, NY, USA) presented the results [2].
CheckMate 901 enrolled 606 participants, of whom 110 had lymph-node-only metastatic disease. The lymph-node-only group showed improved objective response rates (ORR) compared with all randomised participants, regardless of receiving nivolumab/chemotherapy or chemotherapy alone (see Figure).
Figure: Objective response rate in CheckMate 901 [2]
The median progression-free survival (PFS) in lymph-node-only participants was 30.5 months with nivolumab/chemotherapy and 8.8 months with chemotherapy alone (HR 0.38). In all randomised participants, the median PFS was 7.9 versus 7.6 months (HR 0.72). The median overall survival (OS) in lymph-node-only participants was 46.3 months with nivolumab/chemotherapy and 24.9 months with chemotherapy alone (HR 0.58). In all randomised participants, the median OS was 21.7 versus 18.9 months (HR 0.78).
In the nivolumab/chemotherapy arm, 41% of lymph-node-only participants with complete response (CR) experienced a disease-free interval and ongoing response without subsequent therapy after the study treatment ended at 24 months.
“In patients with lymph-node-only mUC, the combination of nivolumab plus gemcitabine/cisplatin induced a durable disease control and clinically meaningful improvements in PFS and OS over gemcitabine/cisplatin alone,” concluded Prof. Galsky.
- Van der Heijden MS, et al. N Engl J Med 2023;389:1778-1789.
- Galsky MD, et al. Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial. Abstract 4509, ASCO Annual Meeting 2024, 31 May–4 June, Chicago, IL, USA.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Metformin does not prevent progression of low-risk prostate cancer Next Article
ctDNA changes as biomarker for pembrolizumab response in advanced urothelial carcinoma »
« Metformin does not prevent progression of low-risk prostate cancer Next Article
ctDNA changes as biomarker for pembrolizumab response in advanced urothelial carcinoma »
Table of Contents: ASCO 2024
Featured articles
Meet the Trialist: Prof. Giuseppe Curigliano on DESTINY-Breast06
Gastrointestinal: Colorectal Cancer
No survival benefit of tumour debulking for patients with multi-organ metastatic CRC
Thermal ablation of small-size colorectal liver metastases is non-inferior to resection
Benefit of first-line nivolumab/ipilimumab in MSI-H/dMMR metastatic CRC
CodeBreaK 300: Promising survival trends in KRAS G12C-mutated mCRC
Gastrointestinal: Upper GI Cancer
FLOT outperforms CROSS in resectable oesophageal cancer
Nivolumab/ipilimumab combination outperforms TKIs in unresectable HCC
No advantage of neoadjuvant radiochemotherapy over neoadjuvant chemotherapy in borderline resectable pancreatic cancer
Breast Cancer
Benefit of abemaciclib plus fulvestrant after progression on a CDK4/6 inhibitor
ctDNA is prognostic of worse outcomes for CDK4/6 therapy
Adjuvant avelumab significantly improves survival in early TNBC
High pCR rate after neoadjuvant Dato-DXd plus durvalumab therapy
Lung Cancer
Osimertinib significantly improves PFS in patients with unresectable stage III EGFR-mutated NSCLC
First-line lorlatinib provides unprecedented improvement for patients with advanced ALK-positive NSCLC
Comparable benefit of video- and in-person-delivered palliative care
Consolidation with durvalumab improves survival in LS-SCLC
Subcutaneous amivantamab non-inferior and more convenient than intravenous amivantamab
Melanoma
Highly significant event-free survival benefit with neoadjuvant nivolumab/ipilimumab in stage III melanoma
Neoadjuvant intralesional daromun improves relapse-free survival in stage III melanoma
Intratumoural tilsotolimod shows no benefit for advanced refractory melanoma
Genitourinary Cancer
Immune-enhancing nutrition does not affect complication rate of radical cystectomy
ctDNA changes as biomarker for pembrolizumab response in advanced urothelial carcinoma
Highest efficacy of nivolumab/chemotherapy in lymph-node-only metastatic urothelial carcinoma
Genitourinary: Prostate Cancer
Metformin does not prevent progression of low-risk prostate cancer
Baseline ctDNA has both prognostic and predictive value in mCRPC
Oxybutynin significantly decreases frequency and severity of hot flashes in men on ADT
Gynaecological Cancer
Batiraxcept shows promise in high AXL-expressing, platinum-resistant ovarian cancer
No lymphadenectomy for advanced ovarian cancer without suspicious nodes
SIENDO: Efficacy benefit of selinexor in TP53 wildtype endometrial cancer
Novel regimen for HR-positive endometrial cancer on the way?
Related Articles
November 26, 2019
Combination of PARP inhibition plus chemotherapy in ovarian cancer
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com